O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×

BP appendices (1).pptx

Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Próximos SlideShares
Indian Pharmacopoeia.pptx
Indian Pharmacopoeia.pptx
Carregando em…3
×

Confira estes a seguir

1 de 21 Anúncio

Mais Conteúdo rRelacionado

Semelhante a BP appendices (1).pptx (20)

Mais recentes (20)

Anúncio

BP appendices (1).pptx

  1. 1. British pharmacopoeia Appendices
  2. 2. Pharmacopoeia, Monogragh • An official publication containing a list of medicinal drugs with their effects and directions for their use. • A pharmacopoeia, pharmacopeia, or pharmacopoea (“drug- making standard”), is a book containing directions for the identification of compound medicines, and published by the authority of a government or a medical or pharmaceutical society. • A monograph includes the name of ingredients or preparations; the definition, packaging, storage and labeling requirements and requirements. The specification consists of a series of tests, procedures for tests, and acceptance criteria.
  3. 3. British pharmacopeia • The British Pharmacopoeia (BP) is the national pharmacopoeia of the United Kingdom. It is an annually published collection of quality standards for UK medicinal substances. • It is a non-profit organisation that owns the trademark and copyright. • Latest edition: • The BP 2020 is the latest edition of the British Pharmacopoeia. This edition becomes legally effective from 1 January 2020.
  4. 4. Editions of British pharmacopeia
  5. 5. Volumes • Volumes I and II • Medicinal Substances • Volume III • Formulated Preparations • Blood related Preparations • Immunological Products • Radiopharmaceutical Preparations • Surgical Materials • Homeopathic Preparations • Volume IV • Appendices • Infrared Reference Spectra • Index • Volume V • British Pharmacopoeia (Veterinary) • Volume VI • (CD-ROM version) • British Pharmacopoeia • British Pharmacopoeia (Veterinary) • British Approved Names
  6. 6. Appendices and indices Appendix 1: Interactions Appendix 2: Borderline substances Appendix 3: Cautionary and advisory labels for diapensed medicines Appendix 4: wound management products and elasticated garments • Dental practitioners' formulary • Nurse prescribers' formulary • Non-medical prescribing • Special order manufacturers
  7. 7. Borderline substances • Borderline substances are mainly foodstuffs, such as enteral feeds and foods that are specially formulated for people with medical conditions. • The Committee has recommended a number of products as complete feeds for certain conditions.They may be prescribed both as sole sources of nutrition and as necessary nutritional supplements prescribable on medical grounds.  Definitions 1. The Committee has defined proven lactose or sucrose intolerance as "A condition of intolerance to an intake of the relevant disaccharide confirmed by: 2. The Committee has defined proven whole protein sensitivity as "Intolerance to whole protein, proven by at least two withdrawal and challenge tests, as suggested by an accurate dietary history."
  8. 8. Cautionary and advisory labels(CALs for diapensed medicines
  9. 9. wound management products and elasticated garments Cotton Absorbent cotton BP Lint Absorbent lint BPC Wound drainage pouches Biotrol draina S Alginate dressings Sorbalgon Hydrogel application Aquaform Odour absorbent dressings CarboFLEX Iodine dressings Iodosorb ointment Permeable adhesive tapes Zinc oxide adhesive tape BP 1988
  10. 10. Dental and nurse prescribers' formulary • Aciclovir Cream BP • Benzydamine Mouthwash, BP 0.15% • Carbamazepine Tablets BP • Diazepam Oral Solution BP 2mg/5ml • Ephedrine Nasal Drops BP • Fluconazole Oral Suspension 50mg/5ml DPF • Hydrocortisone Cream BP 1% • Ibuprofen Tablets BP • Lansoprazole Capsules DPF • Tetracycline Tablets BP
  11. 11. Non-medical prescribing
  12. 12. Special order manufacturers • Licensed hospital manufacturing units also manufacture ‘special-order’ products as unlicensed medicines, the principal NHS units • The MHRA recommends that an unlicensed medicine should only be used when a patient has special requirements that cannot be met by use of a licensed medicine.

×